Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
240
Trial Sponsor
Clinical Trial Start Date
2010
0Primary Completion Date
2014
0Study Completion Date
2014
0Clinical Trial Study Type
Observational0
Observational Clinical Trial Type
Case-Only0
Observational Study Perspective
Cross-Sectional0
Participating Facility
Official Name
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy0
Last Updated
January 19, 2015
0Study summary
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid (DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide information about viral genotypes that may be associated with higher pathogenicity, and help to identify individuals who may be at higher risk of developing Progressive Multifocal Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC Virus (JCV).
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
